These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10882302)

  • 1. Type I receptor tyrosine kinases as targets for therapy in breast cancer.
    Baselga J; Mendelsohn J
    J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):165-74. PubMed ID: 10882302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB receptors as targets for breast cancer therapy.
    Albanell J; Baselga J
    J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):337-51. PubMed ID: 10705918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGF receptor family as targets for cancer therapy.
    Mendelsohn J; Baselga J
    Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeting ErbB receptors in breast cancer].
    Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
    Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor blockade with monoclonal antibodies as anti-cancer therapy.
    Baselga J; Mendelsohn J
    Pharmacol Ther; 1994 Oct; 64(1):127-54. PubMed ID: 7846112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor receptors in breast cancer: potential for therapeutic intervention.
    Nahta R; Hortobágyi GN; Esteva FJ
    Oncologist; 2003; 8(1):5-17. PubMed ID: 12604728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidermal growth factor receptor as a target for therapy in breast carcinoma.
    Baselga J; Mendelsohn J
    Breast Cancer Res Treat; 1994 Jan; 29(1):127-38. PubMed ID: 8018961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
    Albanell J; Codony J; Rovira A; Mellado B; Gascón P
    Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ErbB receptor family: a therapeutic target for cancer.
    de Bono JS; Rowinsky EK
    Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
    Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
    Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.